皮下与静脉阿巴西普治疗类风湿关节炎相关间质性肺病的比较:397例全国多中心研究
全国回顾性多中心研究纳入397例接受阿巴西普治疗的类风湿关节炎相关间质性肺病患者,分为静脉组94例与皮下组303例,中位随访24个月。调整混杂因素后,前24个月用力肺活量(FVC)和一氧化碳弥散量(DLCO)保持稳定且两组间无差异(p=0.6304和0.5337),高分辨率CT(HRCT)肺部病变改善或稳定者占67%(静脉组75% vs 皮下组64%,p=0.07),呼吸困难稳定或改善者占84%(静脉组90% vs 皮下组82%,p=0.09),两组类风湿关节炎疾病活动度均改善,结论认为阿巴西普疗效似乎不因给药途径而异。
要点
- 397例类风湿关节炎相关间质性肺病患者中,静脉阿巴西普94例、皮下阿巴西普303例,中位随访24个月。
- 前24个月FVC和DLCO保持稳定,静脉组与皮下组间无差异(p=0.6304和0.5337)。
- HRCT肺部病变改善或稳定占67%(静脉组75% vs 皮下组64%,p=0.07),呼吸困难稳定或改善占84%(静脉组90% vs 皮下组82%,p=0.09)。
核心结论
- 在类风湿关节炎相关间质性肺病患者中,阿巴西普似乎无论给药途径如何均同等有效。
研究设计与样本
- 全国回顾性多中心研究,纳入397例接受阿巴西普治疗的类风湿关节炎相关间质性肺病患者,分为静脉组94例和皮下组303例,中位随访24[10-48]个月。
- 从基线至末次随访采用线性混合模型分析FVC、DLCO、胸部HRCT、呼吸困难、类风湿关节炎活动度和激素节约效应等结局。
主要发现
- 调整可能混杂因素后,前24个月FVC和DLCO保持稳定,静脉组与皮下组间无差异(p=0.6304和0.5337)。
- HRCT肺部病变改善或稳定见于67%的患者(静脉组75% vs 皮下组64%,p=0.07)。
- 呼吸困难稳定或改善见于84%的患者(静脉组90% vs 皮下组82%,p=0.09)。
- 两组类风湿关节炎疾病活动度均改善,所研究变量在两组间均未发现统计学显著差异。
- 87例(21.9%)停用阿巴西普,静脉组45% vs 皮下组37%(p=0.29),间质性肺病恶化和关节疗效不足是最常见停药原因。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Evidence on abatacept (ABA) utility for rheumatoid arthritis (RA) - associated interstitial lung disease (ILD) is growing. Clinical trials have shown equivalence in subcutaneous (SC) and intravenous (IV) administration of ABA for articular manifestations. However, this has not been studied in respiratory outcomes. OBJECTIVE: To compare the effectiveness of ABA in RA-ILD patients according to the route of administration. METHODS: National retrospective multicentre study of RA-ILD patients on treatment with ABA. They were divided into 2 groups: a) IV, and b) SC. The following outcomes were analysed from baseline to final follow-up using linear mixed models: a) forced vital capacity (FVC), b) diffusing capacity of the lungs for carbon monoxide (DLCO), c) chest high resolution computed tomography (HRCT), d) dyspnoea, e) RA activity, and f) sparing corticosteroids effect. RESULTS: A total of 397 patients were included (94 IV-ABA and 303 SC-ABA), median follow-up of 24 [10-48] months. After adjustment for possible confounders, FVC and DLCO remained stable during the first 24 months without differences between IV-ABA and SC-ABA (p = 0.6304 and 0.5337). Improvement/ stability of lung lesions in HRCT was observed in 67 % of patients (75 % IV-ABA, 64 % SC-ABA; p = 0.07). Dyspnoea stabilized/ improved in 84 % of patients (90 % IV-ABA, 82 % SC-ABA; p = 0.09). RA - disease activity improved in both groups. No statistically significant differences regarding any of the variables studied between the two groups were found. ABA was withdrawn in 87 patients (21.9 %), 45 % IV-ABA and 37 % SC-ABA (p = 0.29). ILD worsening and articular inefficacy were the most common reasons for ABA discontinuation. CONCLUSION: In patients with RA-ILD, ABA seems to be equally effective regardless of the route of administration.
引用
- López-Maraver M, Serrano-Combarro A, Atienza-Mateo B, et al. Subcutaneous vs intravenous abatacept in rheumatoid arthritis-interstitial lung disease. National multicentre study of 397 patients. Semin Arthritis Rheum. 2024. PMID: 39067148. doi:10.1016/j.semarthrit.2024.152517
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。